Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review

Justin E. Swartz¹, Ajit J. Pothen¹, Inge Stegeman¹,², Stefan M. Willems³ & Wilko Grolman¹,²

¹Department of Otorhinolaryngology – Head and Neck Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
²Brain Center Rudolph Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
³Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands

Abstract
Awareness increases that the tumor biology influences treatment outcome and prognosis in cancer. Tumor hypoxia is thought to decrease sensitivity to radiotherapy and some forms of chemotherapy. Presence of hypoxia may be assessed by investigating expression of endogenous markers of hypoxia (EMH) using immunohistochemistry (IHC). In this systematic review we investigated the effect of EMH expression on local control and survival according to treatment modality in head and neck cancer (head and neck squamous cell carcinoma [HNSCC]). A search was performed in MEDLINE and EMBASE. Studies were eligible for inclusion that described EMH expression in relation to outcome in HNSCC patients. Quality was assessed using the Quality in Prognosis Studies (QUIPS) tool. Hazard ratios for locoregional control and survival were extracted. Forty studies of adequate quality were included. HIF-1a, HIF-2a, CA-IX, GLUT-1, and OPN were identified as the best described EMHs. With exception of HIF-2a, all EMHs were significantly related to adverse outcome in multiple studies, especially in studies where patients underwent single-modality treatment. Positive expression was often correlated with adverse clinical characteristics, including disease stage and differentiation grade. In summary, EMH expression was common in HNSCC patients and negatively influenced their prognosis. Future studies should investigate the effect of hypoxia-modified treatment schedules in patients with high EMH expression. These may include ARCON, treatment with nimorazole, or novel targeted therapies directed at hypoxic tissue. Also, the feasibility of surgical removal of the hypoxic tumor volume prior to radiotherapy should be investigated.

Introduction
Despite improvement of surgical and radiotherapeutic techniques, as well as the introduction of systemic therapies including cisplatin or cetuximab, 5-year survival rates for patients with head and neck squamous cell carcinoma (HNSCC) remain low [1]. Currently, staging and treatment selection is based only on clinical staging using the AJCC TNM-classification. However, awareness increases that not all squamous cell carcinomas are the same, but have different tumor biology [2]. These differences could have an even greater impact on treatment outcome than mere clinical staging. An example is infection with the human papillomavirus (HPV) in oropharyngeal squamous cell carcinoma (OPSCC): HPV-associated (HPV+) OPSCC cancers show a much better response to radio- and chemotherapy than non-HPV-associated (HPV−) OPSCC [3, 4]. In this line there is a clear need for other novel biomarkers to predict sensitivity to a particular treatment modality, or to identify which patients might benefit from adjuvant therapies.

One possible target or prognosticator is tumor hypoxia. Hypoxia is defined as a mismatch between cellular oxygen demand and supply. The causes of hypoxia can roughly be divided into two categories: acute or chronic hypoxia. Acute, or perfusion-limited, hypoxia, occurs when there is...
insufficient oxygen supply to cells due to compromise of the supplying blood vessels. Acute hypoxia causes electrolyte imbalances and an increase in intracellular hydrogen sulfide. When this occurs in specialized hypoxia-sensing cells, such as glomus or smooth muscle cells, this leads to a systemic response, such as vasodilation [5]. In contrast, chronic hypoxia triggers a cellular response in individual cells only after several hours of hypoxia [6]. Chronic hypoxia is often caused by diffusion-limitations which occur when the distance from a cell to the nearest blood vessel is too large for adequate cellular oxygenation [7]. Because of expansive tumor growth, chronic hypoxia often occurs in solid tumors, including HNSCC [8]. HNSCC is often treated with radiotherapy which depends on oxygen for free radical formation to induce DNA strand breaks and cell death. Because of the need for oxygen, tumor hypoxia causes decreased sensitivity to radiotherapy. Separately, hypoxia is thought to induce tumor progression and a more aggressive phenotype [9]. Therefore, the hypoxic status of a tumor could possibly contribute in identifying the treatment option that offers the best prognosis to an individual patient. For example, surgical removal of the hypoxic component before radiotherapy might be preferable above radiotherapy alone, when reduced sensitivity to primary radiotherapy is expected. Alternatively, hypoxia-sensitizing radiotherapy schedules such as accelerated radiotherapy with carbogen-breathing and nicotinamide (ARCON) or addition of a hypoxia-sensitizing drug like nimorazole may be considered [10, 11].

Several ways of assessing tumor hypoxia have been described [12]. This includes the invasive Eppendorf \( pO_2 \) histogram, that uses polarographic needles to measure tissue \( pO_2 \) in vivo. Tissue biomarkers for hypoxia may also be used to assess tumor hypoxia histologically. The use of exogenous biomarkers, for instance of the nitroimidazole class, is also invasive, as they have to be administered to patients intravenously before excision of the tissue. Finally, various endogenous biomarkers for hypoxia (EMHs) exist, that can be used to assess the hypoxic state using IHC, with no need for additional invasive procedures other than routine diagnostic biopsy. The most important endogenous biomarkers are part of the hypoxia-inducible factor 1(HIF)-1 pathway. HIF-1 is upregulated under hypoxia to improve cellular survival in a hypoxic microenvironment. This basic helix-loop-helix transcription factor consists of an alpha (HIF-1a) and beta (HIF-1b or ARNT) subunit. Both are constitutively expressed, but under normoxic conditions HIF-1a is quickly degraded by hydroxylation and binding to the VHL protein [13, 14]. In the hypoxic state, hydroxylation of HIF-1a is inhibited, causing stabilization, enabling interaction with HIF-1b and increased transcription of its downstream targets. Another EMH is osteopontin (OPN), which is expressed independently of HIF-1a and is involved in the adhesive cell–matrix interaction and is considered a protein involved in tumor development and progression [15, 16]. A brief review of the studied EMHs is shown in Box 1.

Several (narrative) reviews are currently available on the effect of HIF-1a expression on local control and survival in patients with HNSCC. However, to our knowledge, no systematic reviews have studied EMH expression from a clinical approach, by systematically comparing the effect of all EMHs according to treatment outcome and taking into account differences between subtypes. In the present study, we investigate which biomarkers are used to determine tumor hypoxia in HNSCC, as well as the effect of overexpression on clinical outcome.

**Methods**

**Search strategy**

A systematic review was performed in PubMed/MEDLINE and EMBASE. The search strategy is shown in Table S1.

| Biomarker | Role |
|-----------|------|
| HIF-1a | HIF-1alpha is the alpha subunit of the HIF-1 transcription factor, which is part of the cellular defense mechanisms to survive in a hypoxic state. Under normoxic conditions it is quickly degraded by prolyl hydroxylase (PHD) 1–3. Under hypoxic conditions, PHD activity is inhibited, causing overexpression of HIF-1a. As a transcription factor, HIF-1 stabilization causes increased transcription of its downstream targets through hypoxia-responsive elements (HRE) in the DNA |
| HIF-2a | HIF-2alpha is also a transcription factor in the HIF family, but has distinct other downstream targets. HIF-2a stabilization under hypoxia occurs through the same mechanism as HIF-1a |
| CA-IX | As hypoxic cells rely on anaerobic metabolism, intracellular pH will drop because of lactate formation. Carbonic anhydrase (CA) IX is a downstream target of HIF-1 involved in pH regulation [85]. |
| GLUT-1 | A downstream target of HIF-1a. In hypoxic conditions, additional glucose is required for the anaerobic metabolism. There are many members in the glucose transporter (GLUT-) family, but GLUT-1 is specifically upregulated by HIF-1a |
| OPN | Osteopontin (OPN) is an integrin-binding protein of the SIBLING family (small integrin-binding ligand N-linked glycoprotein) and was first discovered in bone tissue. It promotes cellular survival through the NF-\( \kappa \)B pathway by reducing cell peroxide levels [86]. It is upregulated independent of HIF-1a under hypoxia |

HIF-1, hypoxia-inducible factor 1.
Briefly, a search was performed for studies that described the domain ("HNSCC") and the determinant ("hypoxia"/EMHs) or synonyms of these terms in the title or abstract or as MeSH terms. The MEDLINE GENE database was used to identify synonyms of the various EMHs. Abstracts were screened based on predetermined inclusion and exclusion criteria by two authors independently (Fig. 1). Full-text analysis of potentially relevant abstracts was performed and a final selection was made. At all stages, differences were resolved by discussion. The review was limited to EMHs that were studied in more than two articles.

Relevant full text papers were appraised for risk of bias using the Quality in Prognosis Studies (QUIPS) tool, that has been developed for systematic appraisal in studies of prognostic factors [17]. Using QUIPS, a risk of bias is determined, based on the study design and the reported results. For each of the six domains within QUIPS, the risk of bias was judged low (0 points), moderate (1 point) or high (2 points), based on three to seven predefined criteria per domain. For the current review, the following criteria were used: the source population should consist of a consecutive cohort of patients. Baseline characteristics should include T- and N-staging, as well as the treatment modality. Studies disclosing loss to follow-up and that confirmed whether censored patients were known to be alive at the moment of analysis were valued highest in the "study attrition" appraisal. In the correction for confounding appraisal, studies that investigated potential confounding effects of T- and N-staging, as well as treatment modality were valued highest. Finally, studies that scored a low risk of bias (≤3) were included.

Data extraction and meta-analysis

Extracted data included number of patients, disease stage, tumor subsite, treatment, biomarkers, and corresponding cutoffs and outcome. The studied outcomes were the hazard ratios (HR) for locoregional control (LRC), overall survival (OS), disease-free survival (DFS) and disease-specific survival (DSS). If a HR was not described, but a Kaplan–Meier curve was available, the curve was digitized using the open-source Engauge Digitizer software (http://digitizer.sourceforge.net) and a univariate HR was estimated through the methods of Tierney et al. [18]. Meta-analysis was considered only if studies used the same cutoff values for EMH positivity and described patient cohorts were comparable in terms of treatment and disease stage. A review protocol was not previously published. Results are presented in accordance with the PRISMA statement for systematic reviews [19].

Results

Study selection

The search in EMBASE and PubMed yielded 4684 unique publications. Abstract screening yielded 138 potentially interesting papers, of which the full text was requested. Of these papers, 17 were not in English, Dutch or German, 19 were conference abstracts with no full text paper available and 36 were excluded for various reasons of mismatch with the domain, determinant, or outcome. Sixty-six papers remained for critical appraisal. Relevant reviews were read,
references were screened and a citation check was performed using Web of Science. This yielded three additional papers. The study selection process is shown in Figure 1.

**Critical appraisal**

Using the QUIPS criteria, the 66 and 3 papers identified through the search and citation checks, respectively, were appraised (Table 1 for included studies, Table S2 for excluded studies). In many papers it was not described whether the cohort was consecutive. Also, loss to follow-up and the characteristics of patients lost to follow-up were rarely reported, resulting in a high risk of bias in the “Study Attrition” domain. Many studies used data-dependent cutoffs for their prognostic factor assessment, scoring lower on the “Prognostic factor” domain. Also, the

| Study                                      | SP | SA | PF | O | C | AR | B  | HIF-1α | HIF-2α | CA-IX | GLUT-1 | OPN |
|--------------------------------------------|----|----|----|---|---|----|----|--------|--------|-------|--------|-----|
| Aebersold et al. [20]                      | L  | H  | L  | L | M | L  | 1  |        |        |       |        |     |
| Avirović et al. [35]                      | M  | L  | M  | L | M | L  | 3  |        |        |       |        |     |
| Brockton et al. [48]                      | L  | H  | M  | L | M | L  | 2  |        |        |       |        |     |
| Brockton et al. [33]                      | M  | H  | M  | L | M | L  | 3  |        |        |       |        |     |
| Cabanillas et al. [53]                    | H  | H  | L  | M | M | L  | 3  |        |        |       |        |     |
| Chien et al. [36]                         | H  | H  | L  | L | M | M  | 3  |        |        |       |        |     |
| Chien et al. [37]                         | M  | L  | L  | L | M | L  | 2  |        |        |       |        |     |
| Choi et al. [57]                          | M  | H  | L  | M | M | M  | 3  |        |        |       |        |     |
| Choi et al. [38]                          | M  | L  | L  | L | M | M  | 3  |        |        |       |        |     |
| Dos Santos et al. [39]                    | M  | L  | L  | L | M | L  | 2  |        |        |       |        |     |
| Douglas et al. [22]                       | L  | H  | L  | L | L | L  | 0  |        |        |       |        |     |
| Dunkel et al. [40]                        | L  | H  | L  | M | M | L  | 2  |        |        |       |        |     |
| Eckert et al. [41]                        | H  | L  | L  | M | M | L  | 3  |        |        |       |        |     |
| Eckert et al. [42]                        | H  | L  | L  | L | L | L  | 2  |        |        |       |        |     |
| Eriksen et al. [61]                       | L  | L  | L  | L | L | L  | 0  |        |        |       |        |     |
| Fillies et al. [49]                       | H  | H  | M  | L | L | L  | 3  |        |        |       |        |     |
| Grimm et al. [44]                         | H  | L  | L  | M | M | L  | 3  |        |        |       |        |     |
| Hong et al. [56]                          | L  | L  | L  | L | L | L  | 0  |        |        |       |        |     |
| Hui et al. [31]                           | L  | H  | L  | L | L | L  | 0  |        |        |       |        |     |
| Jonathan et al. [30]                      | M  | L  | L  | L | L | L  | 1  |        |        |       |        |     |
| Kim et al. [51]                           | H  | L  | M  | L | L | L  | 3  |        |        |       |        |     |
| Kitagawa et al. [32]                      | H  | L  | M  | L | L | L  | 3  |        |        |       |        |     |
| Kwon et al. [23]                          | H  | L  | L  | M | M | L  | 3  |        |        |       |        |     |
| Le et al. [58]                            | H  | L  | M  | L | L | L  | 3  |        |        |       |        |     |
| Liang et al. [45]                         | L  | H  | L  | L | H | L  | 2  |        |        |       |        |     |
| Nordmark et al. [29]                      | M  | L  | L  | M | M | M  | 3  |        |        |       |        |     |
| Pérez-Sayans et al. [55]                  | M  | L  | L  | L | M | M  | 3  |        |        |       |        |     |
| Rademakers et al. [24]                    | M  | L  | M  | L | L | L  | 2  |        |        |       |        |     |
| Rahimi et al. [60]                        | L  | H  | L  | L | L | L  | 0  |        |        |       |        |     |
| Roh et al. [52]                           | L  | L  | M  | L | M | L  | 2  |        |        |       |        |     |
| Schrijvers et al. [25]                    | L  | M  | M  | L | L | L  | 1  |        |        |       |        |     |
| Silva et al. [21]                         | M  | H  | L  | L | M | L  | 2  |        |        |       |        |     |
| Van den Broek (2009)                      | L  | H  | M  | L | L | L  | 1  |        |        |       |        |     |
| Wachters et al. [26]                      | L  | H  | L  | L | L | L  | 0  |        |        |       |        |     |
| Wan et al. [59]                           | M  | H  | M  | L | L | L  | 2  |        |        |       |        |     |
| Wildeman et al. [27]                      | M  | L  | L  | M | M | L  | 2  |        |        |       |        |     |
| Winter et al. [54]                        | M  | L  | L  | M | M | L  | 2  |        |        |       |        |     |
| Xueguan et al. [28]                       | L  | L  | L  | M | M | M  | 2  |        |        |       |        |     |
| Zheng et al. [46]                         | M  | H  | L  | L | M | M  | 3  |        |        |       |        |     |
| Zhu et al. [47]                           | L  | H  | M  | L | L | L  | 1  |        |        |       |        |     |
| **Totals**                                 | 27 | 3  | 21 | 7 | 6 |     |     |        |        |       |        |     |

Low, 0; Moderate, 1; High, 2 points. SA was not included. Studies with a bias score >3 were excluded. Appraisal of these studies is described in supplementary table S2. SP, study participation; SA, study attrition; PF, prognostic factor; O, Outcome; C, Confounding; AR, statistical analysis and reporting. B, Bias score according to QUIPS; HIF-1, hypoxia-inducible factor 1. The EMHs that were described in each study are shown with a filled dot (example of filled dot).
treatment modality was often not included in multivariate analysis. As the effect of hypoxia might be different for each treatment modality (e.g., surgery, radiotherapy, or chemoradiation [CRT]), these papers scored a higher risk of bias in the “Confounding” domain, except when the cohort received uniform treatment. A score was calculated as described before, however, the study attrition score was omitted in this final risk of bias score. Forty papers remained for final analysis.

**Endogenous markers of hypoxia**

The included studies described the effect of EMH expression across all subsites in the head and neck area. However, many studies analyzed different staining patterns, methods, and cutoff values to define EMH positivity. For instance, some studies used an H-score that combined staining proportion and intensity, while others only scored staining proportion or intensity. Because of this heterogeneity, it was deemed that data pooling and subsequent meta-analysis were not appropriate, as this might introduce bias.

EMH expression was often correlated with adverse clinical parameters, such as T-stage, N-stage, or differentiation grade, as shown in Tables 2 through 6. The effect of EMH expression is discussed per treatment strategy, as hypoxia may influence outcome of various treatment strategies differently. As a summary, a forest plot for OS across all treatment strategies is shown in Figure 2.

**Primary radiotherapy or ARCON**

Eleven studies were identified that studied the clinical effect of EMHs in patients treated with radiotherapy (XRT) or the hypoxia-sensitizing treatment of accelerated radiotherapy, in combination with carbogen gas breathing and intravenously administered nicotinamide (ARCON) [20–30]. Results are summarized in Table 2. Most studies identified a worse outcome in patients with high EMH expression. This finding appears to be present across all subsites within the head and neck region, including the oropharynx [20, 21], the larynx [23, 25], and the nasopharynx [28], as well as in a study that analyzed patients with cancers of several subsites [29]. In this last study multiple biomarkers of hypoxia were studied. HIF-1α expression predicted significantly worse LRC. While LRC was lower in patients with high expression of CA-IX and OPN, this did not reach statistical significance.

The study of Rademakers et al. [24] of 261 patients randomized between treatment with XRT or ARCON did not find better OS in low CA-IX expressing laryngeal cancer patients (LSCC). Unfortunately, no separate data were presented for XRT and ARCON. The authors did report differences in OS between different staining patterns: a perinecrotic staining pattern, in which cells stain more strongly as the distance to the nearest blood vessel increases, was associated with worse OS ($P < 0.01$) and LRC ($P = 0.01$) when compared to diffuse or no expression of CA-IX. Surprisingly, in the study of Jonathan et al. [30] of 58 HNSCC patients treated only with ARCON, a better outcome was observed in patients with high EMH expression. In this small study, CA-IX expression was mostly low. Using a cutoff at the median value of expression, the authors describe no significant correlation with the outcome. Finally, the 80th percentile (25% membranous expression) was used as a cutoff value that found a significantly better outcome for patients with high CA-IX levels.

**Primary CRT**

Only four studies were available that studied EMH expression in a cohort of patients treated with CRT only [31–34]. A significant effect of EMH expression on survival was found in two [32, 34]. Kitagawa et al. [32] described a cohort of 74 nasopharyngeal cancer (NPC) patients treated with CRT (with exempt of seven patients that did not receive chemotherapy because of kidney failure), patients with more than 10% HIF-1α expression had significantly worse OS. Van den Broek et al. studied HIF-1α expression in a cohort of 91 HNSCC patients and described worse OS, but not LRC in patients with higher HIF-1α expression [34]. Hui et al. studied a cohort of 90 NPC patients and found a trend toward better outcome in low HIF-1α-expressing patients, but did not find a similar trend for CA-IX [31]. Brockton et al. studied CA-IX and GLUT-1 expression in a smaller cohort of 58 patients with primary tumors from various subsites in the head and neck and also did not find a correlation with survival [33] Results are summarized in Table 3.

**Primary surgery**

Thirteen studies studied EMH expression in patients treated with primary surgery only [35–47]. All studies concerned oral cavity carcinoma (OSCC) and all studies, except two, described that in surgically treated patients, HIF-1α expression significantly decreased the prognosis. Choi et al. [38] investigated CA-IX expression in a cohort of 118 patients and did not find an association with prognosis. The study of Dos Santos et al. [39] describes a small subgroup of 36 patients treated only with surgery in a larger cohort of 66 OSCC patients and did not find a difference between high and low HIF-1α-expressing patients. Results are summarized in Table 4.
Eight studies were available that studied EMH expression in a cohort of patients treated with surgery and postoperative radiotherapy [39, 48–54]. Surprisingly, two studies described better prognosis in high HIF-1α expressing patients [39, 49]. The study of Fillies et al. [49] described the effect of HIF-1α expression on clinical outcome and found that HIF-1α expression above 5% results in better survival in OSCC patients. The study of Dos Santos et al. describes a small subgroup of 30 patients treated with surgery and postoperative radiotherapy within a study of 66 OSCC patients [39]. The study of Winter et al. [54] describe significantly worse outcome for HNSCC patients with high HIF-1α expression. All other studies did not show a difference in outcome when patients were stratified according to EMH expression. Results are summarized in Table 5.

### Other treatment strategies

Seven studies describe data from larger cohorts treated with various treatment modalities, depending on localization and staging [55–61]. Only the studies of Rahimi and Le identified a significant correlation between EMH expression and outcome. Rahimi found significant better
Table 2. Clinical outcome: radiotherapy/ARCON.

| Study                | Treatment | Stage | EMH   | Pos/n | Cutoff | Correlations | LRC    | OS     | DFS    | DSS    |
|----------------------|-----------|-------|-------|-------|--------|--------------|--------|--------|--------|--------|
|                      |           |       |       |       |        |              |        |        |        |        |
| Oropharyngeal carcinoma |           |       |       |       |        |              |        |        |        |        |
| Aebersold et al. [20] | XRT       | Any   | HIF-1a| 92/98 | 10% N  | Tumor grade | 0.46 (0.28–0.75) | 0.50 (0.30–0.83) |       |        |
| Silva et al. [21]    | XRT       |       | HIF-1a| 43/79 | 10%    | Low Hb      | 0.2 (0.1–0.42)   |       |        |        |        |
|                      |           |       |       |       |        |              |        |        |        |        |
| Laryngeal carcinoma  |           |       |       |       |        |              |        |        |        |        |
| Douglas et al. [22]  | XRT       | I–II  | HIF-1a| 124/271| 10% N  | None        | 0.96 (0.79–1.16) | LR P = 0.23 |       |        |
| Kwon et al. [23]     | XRT       | I–II  | HIF-1a| 7/42  | 50% N  | ns          | 0.13 (0.02–0.82) |       |        |        |        |
|                      |           | I–II  | CA-IX | 17/42 | 30% M  | ns          | 0.11 (0.01–0.96) |       |        |        |        |
| Rademakers et al. [24]| ARCON/XRT | III–IV| CA-IX | 132/261| Med2   | None        | 0.34 (0.14–0.85) | NS     | 0.34 (0.14–0.82) |       |        |
| Schrijvers et al. [25]| XRT       | I–II  | HIF-1a| 46/91 | 0.5% N  | None        | 0.34 (0.14–0.85) | NS     |        |        |        |
|                      |           | I–II  | CA-IX | 39/91 | 12.5% M | None        | 0.83 (0.04–2.58) |       |        |        |        |
|                      |           | I–II  | GLUT-1| 53/91 | 35% M  | ns          | 0.34 (0.14–0.85) | NS     |        |        |        |
|                      |           | I–II  | OPN   | 20/60 | 0.5% C  | ns          | 0.99 (0.44–2.21) |       |        |        |        |
|                      |           |       |       |       |        |              |        |        |        |        |
| Wachters et al. [26] | XRT       | I–II  | HIF-1a| 47/60 | 0.5% N  | None        | 0.93 (0.26–3.45) |       | 0.81 (0.27–2.38) |       |        |
|                      |           | I–II  | CA-IX | 11/60 | 12.5% M | None        | 0.83 (0.04–2.58) |       |        |        |        |
|                      |           | I–II  | OPN   | 20/60 | 0.5% C  | ns          | 0.99 (0.44–2.21) |       |        |        |        |
| Wildeman et al. [27] | XRT       | Any   | HIF-1a| 59    | N/M %6   | ns          | 1.08 (0.91–1.29)5 |       |        |        |        |
|                      |           | Any   | HIF-1a| 59    | Int     | ns          | 0.92 (0.56–1.49)5 |       |        |        |        |
|                      |           | Any   | CA-IX | 59    | int     | ns          | 1.21 (0.96–1.52)5 |       |        |        |        |
|                      |           |       |       |       |        |              |        |        |        |        |
| Nasopharyngeal carcinoma |         |       |       |       |        |              |        |        |        |        |
| Xueguan et al. [28]  | ARCON     | Any   | HIF-1a| 40/59 | 10% N  | None        | 0.41 (0.06–2.69) | 0.09 (0.01–0.68)6 | 0.26 (0.07–0.97) |       |
|                      |           | Multiple sites | HIF-1a | 19/59 | 50% N | ns          | 0.22 (0.06–0.81) |       |        |        |        |
|                      |           | Multiple sites | CA-IX | 26/57 | 10% M | ns          | 0.35 (0.12–1.01) |       |        |        |        |
|                      |           | Multiple sites | OPN | 17/57 | Int D | ns          | 0.83 (0.35–2.00) |       |        |        |        |
| Jonathan et al. [30] | ARCON     | Any   | CA-IX | 29/58 | 25% M  | ns          | 4.23 (1.07–16.76)6 | NS     |        |        |        |
|                      |           |       | GLUT-1| 29/58 | Int D  | ns          | LR P = 0.001     |        |        |        |        |

The outcomes locoregional control (LRC), overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) are shown as hazard ratio (95% confidence interval). Hazard ratios <1 indicate beneficial prognosis for nonhypoxic tumors. Significant values are shown in bold. Cutoffs were scored according to nuclear (N), membranous (M), cytoplasmic (C), or diffuse (D) staining patterns. XRT: radiotherapy. ARCON: accelerated radiotherapy, carbogen gas breathing and nicotinamide. Pos: number of patients with staining above the mentioned cutoff. LR: Logrank test. ns: not specified. Multiple subsites, patients were not analyzed per subsite. EMH, endogenous markers of hypoxia; HIF-1, hypoxia-inducible factor 1.

1Patients were randomized between ARCON and XRT.
2Computerized image analysis was performed and the median value was used in statistical analyses.
3Supraglottic carcinomas only.
4Analyses were performed using the proportion of membranous or nuclear staining cells as a continuous variable, no cutoff was used. Number of positive staining patients is therefore not relevant.
5Presented numbers are odds-ratios for 2-year locoregional recurrence, not hazard ratios.
6Last surviving patient was scored as deceased to enable HR-calculation, because of 100% survival in one arm.
7Data on immunohistochemical analysis were available for 59 of 67 patients (HIF-1a) and 57/67 patients (CA-IX).
Hypoxia Markers in HNSCC: A Review

Table 3. Clinical outcome: primary chemoradiation.

| Study            | Stage  | EMH     | Pos/n | Cutoff | Correlations | LRC    | OS                      |
|------------------|--------|---------|-------|--------|--------------|--------|-------------------------|
| Nasopharyngeal cancer |        |         |       |        |              |        |                         |
| Hui et al. [31]  | III–IV | HIF-1a  | 32/90 | 5%     | N            | None   | 0.47 (0.21–1.04)         |
|                  |        | CA-IX   | 32/90 | 5%     | M            | None   | 0.72 (0.33–1.56)         |
| Kitagawa et al. [32] | Any    | HIF-1a  | 27/74 | 10%    | N            | None   | 0.49 (0.27–0.88)         |
| Multiple subsites|        |         |       |        |              |        |                         |
| Brockton et al. [33] | II–IV  | CA-IX   | 23/46 | Med    | None         |        | 0.99 (0.35–2.77)         |
|                  |        | GLUT-1  | 24/47 | Med    | None         | LR     | P = 0.79                |
| Van den Broek et al. [34] | Any    | HIF-1a  | 91    | N/M/C/D| ns           | 0.64   | (0.36–1.12)             |
|                  |        | CA-IX   | 91    | N/M/C/D| ns           | 0.73   | (0.43–1.23)             |

The outcomes locoregional control (LRC) and overall survival (OS) are shown as hazard ratio (95% confidence interval). None of the studies reported disease free or disease-specific survival. Hazard ratios <1 indicate beneficial prognosis for nonhypoxic tumors. Significant values are shown in bold. Cutoff: EMHs were scored according to nuclear (N), membranous (M), cytoplasmic (C), or diffuse (D) staining patterns. Pos: number of patients with staining above the mentioned cutoff. LR: Logrank test. ns: not specified. Multiple subsites: patients were not analyzed per subsite. EMH, endogenous markers of hypoxia; HIF-1, hypoxia-inducible factor 1.

1Seven of 74 patients received radiotherapy only due to kidney failure.
2Total 55 patients, data were missing because of missing or folded TMA cores.
3Computerized image analysis was performed, staining pattern was not taken into account.
4Nuclear or membranous expression was analyzed as a continuous variable.

DFS and improved, but not significantly different LRC for patients expressing no or very low levels (<1%) of HIF-1a [60]. Similar results were not obtained for CA-IX. Le et al. [58] studied both CA-IX and OPN expression and found better survival in patients with low CA-IX expression. Pérez-Sayáns et al. (CA-IX), Hong (HIF-1a), and Choi (HIF-1a) did not find a correlation with outcome [55–57]. Wan et al. [59] studied 144 NPC patients randomized to receive neoadjuvant radiotherapy and neoadjuvant CRT followed by CRT and found better, although not statistically significant, OS in low HIF-1a expressing patients. The same results were obtained when both treatment arms were analyzed separately. Results are summarized in Table 6.

Discussion

In this systematic review, we investigated expression of biomarkers for tumor hypoxia in relation to clinical outcome and treatment strategy. We identified 40 high-quality studies. EMH expression was common and associated to worse outcome or LRC in most studies, although statistical significance was not always reached. In addition, EMH expression was often correlated with worse clinicopathological characteristics. Surprisingly, three studies found EMH expression to be associated to better outcome, but these mostly had a small sample size [30, 39, 49]. Moreover, in studies that investigated multiple EMHs, high HIF-1a expression was often associated with worse outcome, while this was not always true for the other EMHs.

Chronic hypoxia is an important and highly prevalent problem in solid tumors [9]. We observed that several adverse clinical parameters were often associated with higher EMH expression, such as the presence of cervical lymph node metastasis, higher T-stages, and worse differentiation grade. The latter two correlations support the hypothesis that hypoxia occurs more often in larger and faster growing tumors. Despite the correlations to clinical parameters, the presence of hypoxia was often an independent predictor of adverse outcome. One explanation might be that in the hypoxic microenvironment, several mechanisms are activated that improve cellular survival under these adverse circumstances. As the HIF-1a transcription factor is stabilized, transcription of proteins increases, including those involved in pH regulation (CA-IX), cellular metabolism (GLUT-1), but also genes involved in angiogenesis or oxygen transport. OPN expression occurs through a hypoxia-dependent, HIF-independent pathway and reduces cell death and apoptosis in hypoxic or reoxygenated cells, it may therefore signify a more aggressive tumor phenotype [15, 16, 62, 63].

Radiotherapy relies on the formation of free oxygen radicals to induce DNA strand breaks and cell death [64]. Also, radiotherapy causes apoptosis through stabilization of p53. The HIF-1 pathway upregulates proteins involved in epithelial-to-mesenchymal transition (EMT), including the transcription factor Snail [65, 66]. Radiation-induced DNA damage is reduced by EMT by emergence of cancer stem cells that express high levels of free radical-scavenging proteins [67]. Moreover, Snail causes radioresistance by suppressing p53-mediated apoptosis [64, 67]. Snail also contributes to cisplatin resistance, which is often concurrently administered to patients as a radiosensitizer.
Thus, hypoxia does not only directly affect (chemo-) radiosensitivity, but also indirectly through EMT.

In this review we identified several studies that show that increased EMH expression leads to worse LRC and survival. However, in patients that were surgically treated only, EMH expression was also associated with worse outcome [35-37, 43, 45]. This supports the hypothesis that hypoxia also contributes to a more aggressive tumor phenotype as described above. Surprisingly, only few studies on HNSCC patients treated with surgery and postoperative (chemo)radiotherapy found an association between EMH expression and survival. A possible explanation is that decreased tumor volume, will lead to better sensitivity to radiotherapy, as was shown by Pameijer and Chen [69, 70]. Dunst and colleagues even described that the hypoxic tumor volume is a better prognosticator than

Table 4. Clinical outcome: primary surgery.

| Study            | Stage | EMH     | Pos/n  | Cutoff                              | Correlations |
|------------------|-------|---------|--------|-------------------------------------|--------------|
|                  |       |         |        |          | OS, DFS, DSS                        |              |
| Avirović et al.  | Any   | OPN     | 48/86  | T-stage, disease stage              | 0.55 (0.3-0.99) |
| Chien et al.     | Any   | OPN     | 30/94  | T-stage, N-stage, tumor thickness,  | LR P < 0.001 |
|                  |       |         |        | tumor necrosis, disease stage       |              |
| Chien et al.     | Any   | OPN     | 192/256| T-stage, N-stage, disease stage     | 0.12 (0.04-0.34) |
| Chien et al.     | Any   | CA-IX   | 64/117 | None                                 | 0.52 (0.21-1.30) |
| Dos Santos et al.| Any   | HIF-1a  | 15/36  | None                                 | LR P = 0.7   |
| Dunkel et al.    | I     | HIF-1a  | 16/44  | ns                                   |              |
| Kang et al.      | I-III | HIF-1a  | 43/49  | T-stage, N-stage, tumor grade       | 0.28 (0.11-0.73) |
| Eckert et al.    | Any   | HIF-1a  | 80     | T-stage                              | 0.21 (0.06-0.72) |
| Eckert et al.    | Any   | GLUT-1  | 80     | T-stage                              | 0.19 (0.05-0.8) |
| Grimm et al.     | Any   | GLUT-1  | 161    | ns                                   | 0.58 (0.37-0.91) |
| Liang et al.     | Any   | HIF-1a  | 89     | Tumor grade, N-stage                | 0.43 (0.20-0.95) |
| Zheng et al.     | Any   | HIF-1a  | 120    | N-stage, disease stage              | 0.72 (0.39-1.32) |
| Zhu et al.       | Any   | HIF-1a  | z97    | T-stage, N-stage, tumor grade       | 0.38 (0.22-0.68) |
|                  |       | HIF-2a  | 97     | T-stage, microvessel density         | 0.78 (0.45-1.37) |

The outcomes overall survival (OS), disease free survival (DFS) and disease specific survival (DSS) are shown as hazard ratio (95% confidence interval). None of the studies reported locoregional control. Hazard ratios < 1 indicate beneficial prognosis for hypoxic tumors. Significant values are shown in bold. Cutoff: EMHs were scored according to nuclear (N), membranous (M), cytoplasmic (C), or diffuse (D) staining patterns. Pos: number of patients with staining above the mentioned cutoff. LR: Logrank test. ns: not specified. Multiple subsites: patients were not analyzed per subsite. EMH, endogenous markers of hypoxia; HIF-1, hypoxia-inducible factor 1.

1Patients from Chien et al. [36] were also included in the sample from Chien et al. [37].
2A score range 0-9 was calculated based on staining proportion and intensity. Staining pattern was not disclosed.
3The scored staining pattern was not disclosed.
4Negative expression (score 0-2): 11, weak (3, 4): 24, moderate (6-8) 38, strong (9-12): 7 patients.
5A score range 0-12 was calculated based on staining proportion and intensity.
6Negative expression (score 0-2): 32, weak (3, 4): 13, moderate (6-8) 21, strong (9-12): 11 patients.
7Both membranous and cytoplasmic (M/C) or nuclear and cytoplasmic (N/C) staining cells were scored positive.
Table 5. Clinical outcome: primary surgery + postoperative radiotherapy.

| Study                  | Stage | EMH       | Pos/n | Cutoff | Correlations | Favor | LRC             | OS             | DFS             | DSS             |
|------------------------|-------|-----------|-------|--------|--------------|-------|-----------------|-----------------|-----------------|-----------------|
| **Oral cavity**        |       |           |       |        |              |       |                 |                 |                 |                 |
| Brockton et al. [48]   | Any   | CA-IX     | 17/61 | p75<sup>1</sup> | ns           | L     | 0.26 (0.06–1.05) |                 |                 |                 |
| Dos Santos et al. [39] | Any   | HIF-1a    | 16/30<sup>2</sup> |        |              | H     | 3.41 (1.13–10.34) |                 |                 |                 |
| Fillies et al. [49]    | I–II  | HIF-1a    | 45/85 | 5% N   | None         | H     | LR < 0.05<sup>3</sup> | LR = 0.02       |                 |                 |
| Han et al [50]         | II    | HIF-1a    | 4/33  | 10% N  | ns           | L     | 0.59 (0.16–2.11) | 0.85 (0.33–2.23) |                 |                 |
| Kim et al. [51]        | Any   | CA-IX     | 38/60 | 10% C/M| Tumor grade, | L     |                 |                 |                 |                 |
|                        |       |           |       |        | subsite, smoking |      |                 |                 |                 |                 |
| Roh et al. [52]        | II    | HIF-1a    | 6/43  | 1% N   | None         | L     | LR = 0.154       |                 |                 |                 |
|                        |       | CA-IX     | 26/43 | 10% M  | Tumor thickness | L    | LR = 0.857     |                 |                 |                 |
|                        |       | GLUT-1    | 31/43 | 50% M  | Tumor thickness, | L    | LR = 0.416     |                 |                 |                 |
|                        |       |           |       |        | n-stage      |       |                 |                 |                 |                 |
| **Laryngeal cancer**   |       |           |       |        |              |       |                 |                 |                 |                 |
| Cabanillas et al. [53] | Any   | HIF-1a    | 75/106| 10% N  | T-stage, disease | N     | LR = 0.8       |                 |                 |                 |
|                        |       |           |       |        | stage        |       |                 |                 |                 |                 |
| **Multiple subsites**  |       |           |       |        |              |       |                 |                 |                 |                 |
| Winter et al. [54]     | Any   | HIF-1a    | 45/151| medN<sup>3</sup> | Disease stage | L     | LR = 0.08      | LR = 0.02       | LR = 0.02       |                 |
|                        |       | HIF-2a    | 21/151| Med NC<sup>3</sup> | None     | L     | LR = 0.43      | LR = 0.10       | LR = 0.16       |                 |
|                        |       | CA-IX     | 92/151| Med M<sup>3</sup> | ns        | L     | LR = 0.3       | LR = 0.2        | LR = 0.1        |                 |

The outcomes locoregional control (LRC), overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) are shown as hazard ratio (95% confidence interval). Hazard ratios <1 indicate beneficial prognosis for nonhypoxic tumors. Significant values are shown in bold. Cutoff: EMHs were scored according to nuclear (N), membranous (M), cytoplasmic (C), or diffuse (D) staining patterns. Pos: number of patients with staining above the mentioned cutoff. Favor: L, better outcome for low expression; H, better outcome for high expression; N, no difference between arms. LR: Logrank test. ns: not specified. Multiple subsites: patients were not analyzed per subsite. EMH, endogenous markers of hypoxia; HIF-1, hypoxia-inducible factor 1.

<sup>1</sup>Computerized image analysis, scoring pattern and value not disclosed.

<sup>2</sup>Subgroup within a larger study of 66 patients.

<sup>3</sup>Exact value not disclosed.
Table 6. Clinical outcome: other treatment strategies.

| Study                  | Treatment                        | Stage       | EMH         | Pos/n  | Cutoff | Correlations          | LRC          | OS            | DFS             | DSS             |
|------------------------|----------------------------------|-------------|-------------|--------|--------|------------------------|--------------|---------------|------------------|------------------|
| Oral cavity cancer     |                                  |             | CA-IX       | 23/50  | 50%    | M                       | Disease stage | 0.34 (0.1–1.2) | 0.72 (0.48–1.03) |                  |
| Pérez-Sayáns et al. [55]| Any                              | Any         | CA-IX       | 23/50  | 50%    | M                       | Disease stage | 0.34 (0.1–1.2) | 0.72 (0.48–1.03) |                  |
| Oropharyngeal cancer   |                                  |             | HIF-1a      | 137/233| 10%    | N                       | T-stage, tumor grade | 0.72 (0.48–1.03) | 0.75 (0.46–1.22) |                  |
| Hong et al. [56]       | Any                              | Any         | HIF-1a      | 26/58  | 1%     | N                       | Disease stage | 0.72 (0.48–1.03) | 0.75 (0.46–1.22) |                  |
| Rahimi et al. [60]     | XRT/CRT                          | Any         | HIF-1a      | 137/233| 10%    | N                       | Disease stage | 0.72 (0.48–1.03) | 0.75 (0.46–1.22) |                  |
| Wan et al. [59]        | nC+C/R/                          | Any         | HIF-1a      | 66/144 | 5%     | C/N                    | Disease stage | 0.72 (0.48–1.03) | 0.75 (0.46–1.22) |                  |
| Multiple subsites      |                                  |             | CA-IX       | 23/50  | 5%     | N                       | Disease stage | 0.72 (0.48–1.03) | 0.75 (0.46–1.22) |                  |
| Choi et al. [57]       | Any                              | Any         | HIF-1a      | 23/50  | 5%     | N                       | Disease stage | 0.72 (0.48–1.03) | 0.75 (0.46–1.22) |                  |
| Eriksen et al. [61]    | Any                              | Any         | CA-IX       | 370    | 5%     | M                       | Disease stage | 0.72 (0.48–1.03) | 0.75 (0.46–1.22) |                  |
| Le et al. [58]         | Any                              | Any         | CA-IX       | 29/94  | Int    | C9                      | Disease stage | 0.72 (0.48–1.03) | 0.75 (0.46–1.22) |                  |
|                        |                                  |             | OPN         | 70/84  | Int    | D                       | Disease stage | 0.72 (0.48–1.03) | 0.75 (0.46–1.22) |                  |

The outcomes locoregional control (LRC), overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) are shown as hazard ratio (95% confidence interval). Hazard ratios <1 indicate beneficial prognosis for nonhypoxic tumors. Significant values are shown in bold. Cutoff: EMHs were scored according to nuclear (N), membranous (M), cytoplasmic (C) or diffuse (D) staining patterns. Pos: number of patients with staining above the mentioned cutoff. LR: Logrank test. ns: not specified. Multiple subsites: patients were not analyzed per subsite. EMH, endogenous markers of hypoxia; HIF-1, hypoxia-inducible factor 1.

1Twenty-three patients had intense staining, 18 patients had moderate staining and 9 patients had no staining.
2Strong vs. no CA-IX staining.
3Chemotherapy was added in the case of T4 or N3 disease.
4Patients participated in a RCT between neoadjuvant chemotherapy followed by either radiotherapy or chemoradiation.
5A score was calculated from 0–16, based on staining proportion and intensity. Both cytoplasmic and nuclear patterns were scored.
6Patients were randomized between radiotherapy or chemotherapy and the radiosensitizer nimorazole.
7Patients were analyzed in groups: <1%, 1–10%, 10–30%, and above 30%. None of these subgroups showed significantly better improvement compared to the other groups.
8Results for CA-IX and OPN were available for 94 and 84 patients, respectively, because of TMA core availability.
9Expression was scored as negative, weak or strong by a single pathologist.
total tumor volume to predict outcome after radiotherapy [71].

Although EMH expression has been well described in HNSCC in current literature, there are still opportunities for future studies. In many publications, EMH expression was studied using tissue microarrays (TMAs) [72]. In a TMA, tumor tissues from multiple patients are placed on a single histological slide [73]. This technique allows for high throughput in determining biomarker expression in patients, but also introduces the risk of sampling bias. Unfortunately, EMH expression may vary widely within tumors, as hypoxia may occur more often in cells that are located distantly from microvessels. This will result in intratumor heterogeneity in the expression of EMH. Positive staining for hypoxic markers is often found in areas of necrosis (perinecrotic staining patterns), which is by some considered proof of “actual hypoxia.” Alternatively, diffuse expression of HIF-1α may also be observed, and is thought to derive from an oncogene-driven overexpression or stabilization of HIF-1α. These expression patterns may be visualized better in whole-slide tissue sections, rather than TMAs. Unfortunately, staining patterns in whole slides have only been described in two studies. Perinecrotic CA-IX staining was associated with worse outcome in a large cohort of LSCC patients treated with ARCON [24]. In fact, staining pattern was a stronger predictor of outcome than the percentage of positive staining cells. In a smaller study of OPSCC patients, there was no difference between perinecrotic and diffuse HIF-1α staining patterns [20].

In the past years, HPV+ HNSCC has emerged as a separate entity with a difference in tumor biology, but also a better response to therapy. There may be differences in the prevalence of tumor hypoxia in HPV+ cancers and tumor hypoxia might also affect the prognosis of HPV+ cancers differently than HPV− cancers. This should be investigated in future studies. Finally, the effect of therapies that focus on hypoxia, either through improvement of tumor oxygenation, or by targeting hypoxic tumor cells should be the subject of future studies. Promising therapies include ARCON, the combination of radiotherapy with carbogen gas breathing and nicotinamide administration, which is currently tested in phase III trials [10, 74]. Delivering increased radiotherapy doses to hypoxic areas in a tumor by IMRT “dose-painting” is also considered, but not yet widely applied [75, 76]. Alternatively, the hypoxia-sensitizer nimorazole may be added to primary radiotherapy [11]. The efficacy of nimorazole administration in HNSCC has been shown in trials within the DAHANCA group [77]. Finally, surgery may also be a treatment option for hypoxic tumors, to decrease the hypoxic or therapy-resistant fraction. While devascularization of the surgical field may lead to hypoxia in the direct postoperative phase, revascularization occurs as early as several days after surgery [78]. This may increase oxygenation, making remaining tumor cells more susceptible to postoperative radiotherapy. Future studies should investigate the feasibility of such a multimodal approach and the effect on survival of patients with hypoxic tumors.

Several limitations of this review and the identified literature should be considered. In the literature, many ways to score biomarker positivity were used. Most studies scored percentages of positive staining cells, while others also took into account staining intensity, or combined the two using a H-score. If HIF-1α expression will be used in treatment selection, a validated, and reproducible scoring strategy should be employed, preferably without software imaging analysis, that may not be available in all centers. Moreover, the different cutoff points, as well as large heterogeneity in terms of tumor subsite and tumor stages did not allow for proper meta-analysis of the extracted data. The cutoff points used in the individual studies were most often the ideal cutoff values for each individual data set, data pooling may introduce bias, and give an overestimation of the effect. Therefore, we have not performed this, in contrast to an earlier review on HIF-1α only [79]. To provide a visual overview of the results, a forest plot is provided.

Another limitation of this review is that we did not include hypoxia gene expression profiles in the search. Several articles describe such profiles in head and neck cancer [80–84]. In the present study we have chosen to focus on IHC, as HNSCC is still highly prevalent in resource-limited areas. Compared to techniques like quantitative PCR (qPCR) or the use of microarrays, IHC may be performed at relatively low cost.

Conclusion

In this systematic review, we identified HIF-1α, HIF-2α, CA-IX, GLUT-1, and OPN as the best studied endogenous markers of tumor hypoxia. In general, expression of these biomarkers was associated with worse survival, almost regardless of the therapy provided. These proteins are not only biomarkers, but are also part of cellular survival mechanisms. Therefore, EMH overexpression may result in worse prognosis not only due to hypoxia, but also because of a more aggressive tumor phenotype. The effect of tumor hypoxia in HNSCC patients warrants further investigation. Studies should investigate the best treatment option for hypoxic tumors, for instance hypoxia-modified radiotherapy schedules, targeted therapies against hypoxic cells or excision of the hypoxic tissue to improve radiation sensitivity. Knowledge on the tumor hypoxia status will help clinicians to select tailored treatments for each individual patient and thus enable personalized cancer care.
Conflict of Interest

None declared.

References

1. Pulte, D., and H. Brenner. 2010. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 15:994–1001.
2. Leemans, C. R., B. J. M. Braakhuis, and R. H. Brakenhoff. 2010. The molecular biology of head and neck cancer. Nat. Rev. Cancer 11:9–22.
3. Masterson, L., D. Moualed, Z. W. Liu, J. E. F. Howard, R. C. Dwivedi, J. R. Tysome, et al. 2014. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. Eur. J. Cancer 50:2636–2648.
4. Kimple, R. J., M. A. Smith, G. C. Blitzer, A. D. Torres, J. A. Martin, R. Z. Yang, et al. 2013. Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res. 73:4791–4800.
5. Taabazuing, C. Y., J. A. Hangasky, and M. J. Knapp. 2014. Oxygen sensing strategies in mammals and bacteria. J. Inorg. Biochem. 133:1–72.
6. Nguyen, L. K., M. A. Cavadas, C. C. Scholz, S. F. Fitzpatrick, U. Bruning, E. P. Cummins, et al. 2013. A dynamic model of the hypoxia-inducible factor 1 (HIF-1) network. J. Cell Sci. 126:1454–1463.
7. Denko, N. C. 2008. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 8:705–713.
8. Höckel, M., and P. Vaupel. 2001. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93:266–276.
9. Mayer, A., P. Vaupel. 2013. Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? Pp. 203–209 in S. Van Huffel, G. Naulaers, A. Caicedo, D. F. Bruley, D. K. Harrison, eds. Advances in experimental medicine and biology. Vol. 789. Adv Exp Med Biol. Springer, New York, NY.
10. Kaanders, J. H. A. M., J. Bussink, and A. J. van der Kogel. 2002. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol. 3:728–737.
11. Timothy, A. R., J. Overgaard, and M. Overgaard. 1984. A phase I clinical study of Nimorazole as a hypoxic radiosensitizer. Int. J. Radiat. Oncol. Biol. Phys. 10:1765–1768.
12. Hoogsteen, I. J., H. A. M. Marres, J. Bussink, A. J. van der Kogel, and J. H. A. M. Kaanders. 2007. Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. Head Neck 29:591–604.
13. Ivan, M., K. Kondo, H. Yang, W. Kim, J. Vialiando, M. Ohh, et al. 2001. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292:464–468.
14. Berra, E., E. Benizri, A. Ginouvès, V. Volmat, D. Roux, and J. Pouyssegur. 2003. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 22:4082–4090.
15. Zhu, Y., D. T. Denhardt, H. Cao, P. D. Sutphin, A. C. Koong, A. J. Giaccia, et al. 2005. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 24:6555–6563.
16. Le, Q.-T., N. C. Denko, and A. J. Giaccia. 2004. Hypoxic gene expression and metastasis. Cancer Metastasis Rev. 23:293–310.
17. Hayden, J. A., D. A. van der Windt, J. L. Cartwright, P. Côté, and C. Bombardier. 2013. Assessing bias in studies of prognostic factors. Ann. Intern. Med. 158:280–286.
18. Tierney, J. F., L. A. Stewart, D. Gherzi, S. Burdett, and M. R. Sydes. 2007. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16.
19. Moher, D., A. Liberati, J. Tetzlaff, and D. G. Altman. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6:e1000097.
20. Aebersold, D. M., P. Burri, K. T. Beer, J. Laissue, V. Djonov, R. H. Greiner, et al. 2001. Expression of hypoxia-inducible factor-1alpha in normoxia. EMBO J. 22:4082–4090.
21. Silva, P., N. J. Slevin, P. Sloan, H. Valentine, J. Cresswell, A. Merve, R. Swindell, et al. 2013. Lack of prognostic significance of tumor hypoxia inducible factor-1alpha expression for outcome and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? Pp. 203–209 in S. Van Huffel, G. Naulaers, A. Caicedo, D. F. Bruley, D. K. Harrison, eds. Advances in experimental medicine and biology. Vol. 789. Adv Exp Med Biol. Springer, New York, NY.
22. Douglas, C. M., J. M. Bernstein, V. E. Ormston, R. C. Hall, A. Merve, R. Swindell, et al. 2013. Lack of prognostic effect of carbonic anhydrase-9, hypoxia inducible factor-1z and bcl-2 in 286 patients with early squamous cell carcinoma of the glottic larynx treated with radiotherapy. Clin. Oncol. 25:59–65.
23. Kwon, O. J., J. J. Park, G. H. Ko, J. H. Seo, B. Jeong, K. M. Kang, et al. 2014. HIF-1z and CA-IX as predictors of locoregional control for determining the optimal treatment modality for early-stage laryngeal carcinoma. Head Neck 37:505–510.
24. Rademakers, S. E., I. J. Hoogsteen, P. F. Rijken, E. Oosterwijk, C. H. Terhaard, P. A. Doornmaert, et al. 2013. Pattern of CAIX expression is prognostic for outcome and predicts response to ARCON in patients with laryngeal cancer treated in a phase III randomized trial. Radiother. Oncol. 108:517–522.
25. Schrijvers, M. L., B. F. van der Laan, G. H. de Bock, W. J. Pattje, M. F. Mastik, L. Menkema, et al. 2008.
Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 72:161–169.

26. Wachters, J. E., M. L. Schrijvers, L. Slager-Menkema, M. Mastik, G. H. de Bock, J. A. Langendijk, et al. 2013. Prognostic significance of HIF-1a, CA-IX, and OPN in T1-T2 laryngeal carcinoma treated with radiotherapy. Laryngoscope 123:2154–2160.

27. Wildeman, M. A., J. H. Gibcus, M. Hauptmann, A. C. Begg, M. L. F. van Velthuyzen, F. J. Hoebers, et al. 2009. Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response? Laryngoscope 119:316–322.

28. Xueguan, L., W. Xiaoshen, Z. Yongsheng, H. Chaosu, S. Chunying, and F. Yan. 2008. Hypoxia inducible factor-1 alpha and vascular endothelial growth factor expression are associated with a poor prognosis in patients with nasopharyngeal carcinoma receiving radiotherapy with carbogen and nicotinamide. Clin. Oncol. 20:606–612.

29. Nordsmark, M., J. G. Eriksen, V. Gebski, J. Alsner, M. R. Horsman, and J. Overgaard. 2007. Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother. Oncol. 83:389–397.

30. Jonathan, R. A., K. I. E. M. Wijffels, W. Peeters, P. C. M. de Wilde, H. A. M. Marres, M. A. W. Merkx, et al. 2006. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother. Oncol. 79:288–297.

31. Hui, E. P., A. T. C. Chan, F. Pezzella, H. Turley, K. To, T. C. W. Poon, et al. 2002. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin. Cancer Res. 8:2595–2604.

32. Kitagawa, N., S. Kondo, N. Wakisaka, Y. Zen, Y. Nakanishi, A. Tsuji, et al. 2013. Expression of seven-in-absentia homologue 1 and hypoxia-inducible factor 1 alpha: novel prognostic factors of nasopharyngeal carcinoma. Cancer Lett. 331:52–57.

33. Brockton, N., J. Dort, H. Lau, D. Hao, S. Brar, A. Klimowicz, et al. 2011. High stromal carbonic anhydrase ix expression is associated with decreased survival in p16-negative head-and-neck tumors. Int. J. Radiat. Oncol. Biol. Phys. 80:249–257.

34. Van den Broek, G. B., M. A. M. Wildeman, C. R. N. Rasch, N. Armstrong, E. Schuuring, A. C. Begg, et al. 2009. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int. J. Cancer 124:2643–2650.

35. Avirovič, M., K. Matusšan-Ilijaš, G. Damante, D. Fabbro, R. Cerović, M. Juretić, et al. 2013. Osteopontin expression is an independent factor for poor survival in oral squamous cell carcinoma: a computer-assisted analysis on TMA sections. J. Oral Pathol. Med. 42:620–626.

36. Chien, C., C. Su, H. Chuang, F. Fang, H.-Y. Huang, C.-M. Chen, et al. 2008. Clinical significance of osteopontin expression in T1 and T2 tongue cancers. Head Neck 30:776–781.

37. Chien, C.-Y., C.-Y. Su, H.-C. Chuang, F.-M. Fang, H.-Y. Huang, C.-H. Chen, et al. 2009. Comprehensive study on the prognostic role of osteopontin expression in oral squamous cell carcinoma. Oral Oncol. 45:798–802.

38. Choi, S.-W., J.-Y. Kim, J.-Y. Park, I.-H. Cha, J. Kim, and S. Lee. 2008. Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma. Hum. Pathol. 39:1317–1322.

39. Dos Santos, M., A. M. D. C. Mercante, I. D. Louro, A. J. Gonçalves, M. B. de Carvalho, E. H. T. da Silva, et al. 2012. HIF1-alpha expression predicts survival of patients with squamous cell carcinoma of the oral cavity. PLoS One 7:e45228.

40. Dunkel, J., S. Vaittinen, R. Grénman, I. Kinnunen, and H. Irjala. 2013. Prognostic markers in stage I oral cavity squamous cell carcinoma. Laryngoscope 123:2435–2441.

41. Eckert, A. W., A. Schütze, M. H. W. Lautner, H. Taubert, J. Schubert, and U. Bilkenroth. 2010. HIF-1alpha is a prognostic marker in oral squamous cell carcinomas. Int. J. Biol. Markers 25:87–92.

42. Eckert, A. W., M. H. W. Lautner, A. Schütze, H. Taubert, J. Schubert, and U. Bilkenroth. 2011. Coexpression of hypoxia-inducible factor-1α and glucose transporter-1 is associated with poor prognosis in oral squamous cell carcinoma patients. Histopathology 58:1136–1147.

43. Kang, F.-W., Y. Gao, L. Que, J. Sun, and Z.-L. Wang. 2013. Hypoxia-inducible factor-1α overexpression indicates poor clinical outcomes in tongue squamous cell carcinoma. Exp. Ther. Med. 5:112–118.

44. Grimm, M., A. Munz, P. Teriete, T. Nadototschi, and S. Reinert. 2014. GLUT-1(+)/TKTL1(+) coexpression predicts poor outcome in oral squamous cell carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 117:743–753.

45. Liang, X., M. Zheng, J. Jiang, G. Zhu, J. Yang, and Y. Tang. 2011. Hypoxia-inducible factor-1 alpha, in association with TWIST2 and SNIP1, is a critical prognostic factor in patients with tongue squamous cell carcinoma. Oral Oncol. 47:92–97.

46. Zheng, Y., Y. Ni, X. Huang, Z. Wang, and W. Han. 2013. Overexpression of HIF-1α indicates a poor prognosis in tongue carcinoma and may be associated with tumour metastasis. Oncol. Lett. 5:1285–1289.

47. Zhu, G., Y. Tang, L. Li, M. Zheng, J. Jiang, X. Li, et al. 2010. Hypoxia inducible factor 1α and hypoxia inducible factor 2α play distinct and functionally overlapping roles
in oral squamous cell carcinoma. Clin. Cancer Res. 16:4732–4741.
48. Brockton, N. T., A. C. Klimowicz, P. Bose, S. K. Petrillo, M. Konno, L. Rudmik, et al. 2012. High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma. Oral Oncol. 48:615–622.
49. Fillies, T., R. Werkmeister, P. J. van Diest, B. Brandt, U. Han, M. W., H. J. Lee, K.-J. Cho, J. S. Kim, J.-L. Roh, S.-K. Baek, B. K. Shin, J. F. Reibel, et al. 2012. Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head Neck 34:1395–1402.
50. Kim, S. J., H. J. Shin, K.-Y. Jung, S.-K. Baek, B. K. Shin, J. Choi, et al. 2007. Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. Jpn. J. Clin. Oncol. 37:812–819.
51. Roh, J.-L., K.-J. Cho, G. Y. Kwon, C. H. Ryu, H. W. Chang, S.-H. Choi, et al. 2009. The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Oral Oncol. 45:63–68.
52. Cabanillas, R., J. P. Rodrigo, P. Secades, A. Astudillo, C. S. Nieto, and M. D. Chiara. 2009. The relation between hypoxia-inducible factor (HIF)-1alpha expression with p53 expression and outcome in surgically treated supraglottic laryngeal cancer. J. Surg. Oncol. 99:373–378.
53. Winter, S. C., K. A. Shah, C. Han, L. Campo, H. Turley, R. Leek, et al. 2006. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 107:757–766.
54. Pérez-Sayáns, M., J. M. Suárez-Peña, D.-G. Pilar, C. T. Supuran, S. Pastorekova, F. Barros-Angueira, et al. 2012. Expression of CA-IX is associated with advanced stage tumors and poor survival in oral squamous cell carcinoma patients. J. Oral Pathol. Med. 41:667–674.
55. Hong, A., M. Zhang, A.-S. Veillard, J. Jahanbani, C. S. Lee, D. Jones, et al. 2013. The prognostic significance of hypoxia inducing factor 1-α in oropharyngeal cancer in relation to human papillomavirus status. Oral Oncol. 49:354–359.
56. Choi, H. G., J.-S. Kim, K. H. Kim, K. H. Kim, M.-W. Sung, J.-Y. Choe, et al. 2014. Expression of hypoxic signaling markers in head and neck squamous cell carcinoma and its clinical significance. Eur. Arch. Otorhinolaryngol. 272:219–228.
57. Le, Q.-T., C. Kong, P. W. Lavori, K. O’Byrne, J. T. Erler, X. Huang, et al. 2007. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 69:167–175.
58. Wan, X.-B., X.-J. Fan, P.-Y. Huang, D. Dong, Y. Zhang, M.-Y. Chen, et al. 2012. Aurora-A activation, correlated with hypoxia-inducible factor-1α, promotes radiochemoresistance and predicts poor outcome for nasopharyngeal carcinoma. Cancer Sci. 103:1586–1594.
59. Rahimi, A. S., D. D. Wilson, D. K. Saylor, E. B. Stelow, C. Y. Thomas, J. F. Reibel, et al. 2012. p16, Cyclin D1, and HIF-1α Predict Outcomes of Patients with Oropharyngeal Squamous Cell Carcinoma Treated with Definitive Intensity-Modulated Radiation Therapy. Int. J. Otolaryngol. 2012:685951.
60. Eriksen, J. G., and J. Overgaard. 2007. Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. Radiother. Oncol. 83:383–388.
61. Bandopadhyay, M., A. Bulbule, R. Butti, G. Chakraborty, P. Ghormade, P. Ghosh, et al. 2014. Osteopontin as a therapeutic target for cancer. Expert Opin. Ther. Targets 18:883–895.
62. Denhardt, D. T., C. A. Lopez, E. E. Rollo, S. M. Hwang, X. R. An, and S. E. Walther. 1995. Osteopontin-induced modifications of cellular functions. Ann. N. Y. Acad. Sci. 760:127–142.
63. Cohen-Jonathan, E., E. J. Bernhard, and W. G. McKenna. 1999. How does radiation kill cells? Curr. Opin. Chem. Biol. 3:77–83.
64. Tsai, Y.-P., and K.-J. Wu. 2012. Hypoxia-regulated target genes implicated in tumor metastasis. J. Biomed. Sci. 19:102.
65. Zhang, L., G. Huang, X. Li, Y. Zhang, Y. Jiang, J. Shen, et al. 2013. Hypoxia induces epithelial-mesenchymal transition via activation of SNAIL by hypoxia-inducible factor-1α in hepatocellular carcinoma. BMC Cancer. BMC Cancer 13:108.
66. Nantajit, D., D. Lin, and J. J. Li. 2014. The network of epithelial–mesenchymal transition: potential new targets for tumor resistance. J. Cancer Res. Clin. Oncol. DOI: 10.1007/s00432-014-1840-y.
67. Hsu, D. S. S., H. Y. Lan, C. H. Huang, S. K. Tai, S. Y. Chang, T. L. Tsai, et al. 2010. Regulation of excision repair cross-complementation group 1 by snail contributes to cisplatin resistance in head and neck cancer. Clin. Cancer Res. 16:4561–4571.
68. Pameijer, F. A., A. A. Mancuso, W. M. Mendenhall, J. T. Parsons, and P. S. Kubilis. 1997. Can pretreatment computed tomography predict local control in T3 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy? Int. J. Radiat. Oncol. Biol. Phys. 37:1011–1021.
69. Chen, S.-W., S.-N. Yang, J.-A. Liang, M.-H. Tsai, A.-C. Shiau, and F.-J. Lin. 2006. Value of computed tomography-based tumor volume as a predictor of
outcomes in hypopharyngeal cancer after treatment with definitive radiotherapy. Laryngoscope 116:2012–2017.
71. Dünst, J., P. Stadler, A. Becker, C. Lautenschläger, T. Pelz, G. Hänsgen, et al. 2003. Tumor volume and tumor hypoxia in head and neck cancers. Strahlenther. Onkol. 179:521–526.
72. Kallioniemi, O. P., U. Wagner, J. Kononen, and G. Sauter. 2001. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum. Mol. Genet. 10:657–662.
73. Noorlag, R., P. van der Groep, F. K. J. Leusink, S. R. van Hooff, M. H. Frank, S. M. Willems, et al. 2014. Nodal metastasis and survival in oral cancer: association with protein expression of SLPI, not with LCN2, TACSTD2, or THBS2. Head Neck DOI: 10.1002/hed.23716.
74. Janssens, G. O., S. E. Rademakers, C. H. Terhaard, P. Doornaert, H. P. Bijl, P. van den Ende, et al. 2014. Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer. Clin. Cancer Res. 20:1345–1354.
75. Chang, J. H., M. Wada, N. J. Anderson, D. Lim Joon, S. T. Lee, S. J. Gong, et al. 2013. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study. Acta Oncol. 52:1723–1729.
76. Grosu, A. L., M. Souvatzoglou, B. Röper, M. Dobritz, N. Wiedenmann, V. Jacob, et al. 2007. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 69:541–551.
77. Bentzen, J., K. Toustrup, J. G. Eriksen, H. Primdahl, L. J. Andersen, and J. Overgaard. 2015. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. Acta Oncol. DOI: 10.3109/0284186X.2014.929547.
78. Kumar, I., C. A. Staton, S. S. Cross, M. W. R. Reed, and N. J. Brown. 2009. Angiogenesis, vascular endothelial growth factor and its receptors in human surgical wounds. Br. J. Surg. 96:1484–91.
79. Gong, L., W. Zhang, J. Zhou, J. Lu, H. Xiong, X. Shi, et al. 2013. Prognostic value of HIFs expression in head and neck cancer: a systematic review. PLoS One 8:e75094.
80. Winter, S. C., F. M. Buffa, P. Silva, C. Miller, H. R. Valentine, H. Turley, et al. 2007. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 67:3441–3449.
81. Buffa, F. M., A. L. Harris, C. M. West, and C. J. Miller. 2010. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br. J. Cancer 102:428–435.
82. Eustace, A., N. Mani, P. N. Span, J. J. Irlam, J. Taylor, G. Nj, et al. 2013. A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. Clin. Cancer Res. 19:4879–4888.
83. Toustrup, K., B. S. Sørensen, M. Nordmark, M. Busk, C. Wiuf, J. Alsner, et al. 2011. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 71:5923–5931.
84. Toustrup, K., B. S. Sørensen, P. Lassen, C. Wiuf, J. Alsner, and J. Overgaard. 2012. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother. Oncol. 102:122–129.
85. Sedlakova, O., E. Svastova, M. Takacova, J. Kopacek, J. Pastorek, and S. Pastorekova. 2014. Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Front. Physiol. 4:400.
86. Xie, Y., M. Sakatsume, S. Nishi, I. Narita, M. Arakawa, and F. Gejyo. 2001. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int. 60:1645–1657.

Supporting Information
Additional Supporting Information may be found in the online version of this article:
Table S1. Search strategy.
Table S2. Critical appraisal of the excluded studies.
Table S3. PRISMA checklist.